Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor

Takehiko Mori, Yoshinobu Aisa, Takayuki Shimizu, Tomonori Nakazato, Rie Yamazaki, Yasuo Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In this prospective single-center study, we evaluated the efficacy and safety of valaciclovir (VACV) in the prevention of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation (BMT). The study population consisted of 12 patients who underwent allogeneic BMT from an unrelated donor. Patients received acyclovir (ACV) intravenously until they became able to take VACV orally. VACV was administered at a daily dose of 3000 mg and continued until day 100. CMV infection was monitored by CMV antigenemia assay and real-time polymerase chain reaction analysis of plasma. Thirty-five patients who did not receive any form of CMV chemoprophylaxis served as control subjects. CMV infection was detected in 4 (33.3%) of the 12 patients and in 24 (68.6%) of the 35 control subjects (P < .05). The onset of CMV infection was significantly delayed in the VACV group (median, day 43) compared with the control group (median, day 28.5; P < .01). Gastrointestinal symptoms as an adverse event due to VACV administration were observed in 2 patients. The plasma levels of ACV after VACV administration were measured in 8 patients and were similar to those in the healthy subjects. In conclusion, VACV shows normal absorption, even in the early posttransplantation period, and may prevent or delay CMV infection effectively and safely in allogeneic BMT recipients.

Original languageEnglish
Pages (from-to)266-270
Number of pages5
JournalInternational Journal of Hematology
Volume83
Issue number3
DOIs
Publication statusPublished - 2006 Apr

Fingerprint

valacyclovir
Unrelated Donors
Homologous Transplantation
Cytomegalovirus Infections
Bone Marrow Transplantation
Acyclovir
Cytomegalovirus
Chemoprevention
Real-Time Polymerase Chain Reaction
Healthy Volunteers

Keywords

  • Allogeneic BMT
  • Cytomegalovirus
  • Valaciclovir

ASJC Scopus subject areas

  • Hematology

Cite this

@article{547a2dac5d3f4789bf6271d31a3cccde,
title = "Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor",
abstract = "In this prospective single-center study, we evaluated the efficacy and safety of valaciclovir (VACV) in the prevention of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation (BMT). The study population consisted of 12 patients who underwent allogeneic BMT from an unrelated donor. Patients received acyclovir (ACV) intravenously until they became able to take VACV orally. VACV was administered at a daily dose of 3000 mg and continued until day 100. CMV infection was monitored by CMV antigenemia assay and real-time polymerase chain reaction analysis of plasma. Thirty-five patients who did not receive any form of CMV chemoprophylaxis served as control subjects. CMV infection was detected in 4 (33.3{\%}) of the 12 patients and in 24 (68.6{\%}) of the 35 control subjects (P < .05). The onset of CMV infection was significantly delayed in the VACV group (median, day 43) compared with the control group (median, day 28.5; P < .01). Gastrointestinal symptoms as an adverse event due to VACV administration were observed in 2 patients. The plasma levels of ACV after VACV administration were measured in 8 patients and were similar to those in the healthy subjects. In conclusion, VACV shows normal absorption, even in the early posttransplantation period, and may prevent or delay CMV infection effectively and safely in allogeneic BMT recipients.",
keywords = "Allogeneic BMT, Cytomegalovirus, Valaciclovir",
author = "Takehiko Mori and Yoshinobu Aisa and Takayuki Shimizu and Tomonori Nakazato and Rie Yamazaki and Yasuo Ikeda and Shinichiro Okamoto",
year = "2006",
month = "4",
doi = "10.1532/IJH97.E0523",
language = "English",
volume = "83",
pages = "266--270",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor

AU - Mori, Takehiko

AU - Aisa, Yoshinobu

AU - Shimizu, Takayuki

AU - Nakazato, Tomonori

AU - Yamazaki, Rie

AU - Ikeda, Yasuo

AU - Okamoto, Shinichiro

PY - 2006/4

Y1 - 2006/4

N2 - In this prospective single-center study, we evaluated the efficacy and safety of valaciclovir (VACV) in the prevention of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation (BMT). The study population consisted of 12 patients who underwent allogeneic BMT from an unrelated donor. Patients received acyclovir (ACV) intravenously until they became able to take VACV orally. VACV was administered at a daily dose of 3000 mg and continued until day 100. CMV infection was monitored by CMV antigenemia assay and real-time polymerase chain reaction analysis of plasma. Thirty-five patients who did not receive any form of CMV chemoprophylaxis served as control subjects. CMV infection was detected in 4 (33.3%) of the 12 patients and in 24 (68.6%) of the 35 control subjects (P < .05). The onset of CMV infection was significantly delayed in the VACV group (median, day 43) compared with the control group (median, day 28.5; P < .01). Gastrointestinal symptoms as an adverse event due to VACV administration were observed in 2 patients. The plasma levels of ACV after VACV administration were measured in 8 patients and were similar to those in the healthy subjects. In conclusion, VACV shows normal absorption, even in the early posttransplantation period, and may prevent or delay CMV infection effectively and safely in allogeneic BMT recipients.

AB - In this prospective single-center study, we evaluated the efficacy and safety of valaciclovir (VACV) in the prevention of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation (BMT). The study population consisted of 12 patients who underwent allogeneic BMT from an unrelated donor. Patients received acyclovir (ACV) intravenously until they became able to take VACV orally. VACV was administered at a daily dose of 3000 mg and continued until day 100. CMV infection was monitored by CMV antigenemia assay and real-time polymerase chain reaction analysis of plasma. Thirty-five patients who did not receive any form of CMV chemoprophylaxis served as control subjects. CMV infection was detected in 4 (33.3%) of the 12 patients and in 24 (68.6%) of the 35 control subjects (P < .05). The onset of CMV infection was significantly delayed in the VACV group (median, day 43) compared with the control group (median, day 28.5; P < .01). Gastrointestinal symptoms as an adverse event due to VACV administration were observed in 2 patients. The plasma levels of ACV after VACV administration were measured in 8 patients and were similar to those in the healthy subjects. In conclusion, VACV shows normal absorption, even in the early posttransplantation period, and may prevent or delay CMV infection effectively and safely in allogeneic BMT recipients.

KW - Allogeneic BMT

KW - Cytomegalovirus

KW - Valaciclovir

UR - http://www.scopus.com/inward/record.url?scp=33745941221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745941221&partnerID=8YFLogxK

U2 - 10.1532/IJH97.E0523

DO - 10.1532/IJH97.E0523

M3 - Article

C2 - 16720561

AN - SCOPUS:33745941221

VL - 83

SP - 266

EP - 270

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -